NEW YORK – Singapore-based Lucence Diagnostics and China's MEDx (Suzhou) Translational Medicine announced on Wednesday a strategic partnership aimed at cancer in China.
Under the agreement, the firms will codevelop companion diagnostic tests for PD-L1 rearrangement to be used with anti-PD1/PD-L1 cancer immunotherapies. Financial and other terms of the agreement were not disclosed.